Table 5.
Association of the mRNA expression level of Notch4 with clinicopathological characteristics of patients.
| Variables | Expression of Notch4 |
OR | 95% CI | P-Value | |
|---|---|---|---|---|---|
| Low (%) | High (%) | ||||
| Grade | 0.640 | ||||
| Grade 1 | 12 (34.3%) | 20 (57.1%) | 0.245-1.672 | 0.362 | |
| Grades 2 & 3 | 25 (67%) | 15 (42.9%) | |||
| N stage | 12.267 | 3.769-39.634 | 0.0001 | ||
| N0 & N1 | 32 (86.5%) | 12 (34.3%) | |||
| N1 & N2 | 5 (13.5%) | 23 (65.7%) | |||
| T Stage | 2.236 | 0.760-6.577 | 0.144 | ||
| T1 & T2 | 30 (81.1%) | 23 (65.7%) | |||
| T3 & T4 | 7 (18.9%) | 12 (34.3%) | |||
| Extracapsular nodal extension | 0.264 | 0.075-0.932 | 0.038 | ||
| Yes | 33 (89.2%) | 24 (68.6%) | |||
| No | 14 (37.8%) | 11 (31.4%) | |||
| DCIS histology | 1.167 | 0.445-3.058 | 0.754 | ||
| Comedo Type | 23 (62.2%) | 12 (34.3%) | |||
| Non Comedo | 34 (91.9%) | 23 (65.7%) | |||
| Nipple involvement | 0796 | 0.630-1.006 | 0.056 | ||
| No | 34 (91.9%) | 26 (74.3%) | |||
| Yes | 7 (8.1%) | 9 (25.7%) | |||
| Lymphatic invasion | 0.922 | 0.310-2.740 | 0.884 | ||
| No | 9 (24.3%) | 8 (22.9%) | |||
| Yes | 28 (75.7%) | 27 (77.1%) | |||
| Perineural invasion | 0.723 | 0.282-1.851 | 0.499 | ||
| Yes | 23(62.2%) | 19(54.3%) | |||
| No | 14(37.8%) | 16(45.7%) | |||
| PR status | 1.038 | 0.39-2.741 | 0.940 | ||
| Positive | 24 (64.9%) | 23 (65.7%) | |||
| Negative | 13 (35.1%) | 12 (34.3%) | |||
| HER-2 status | 1.244 | 0.436-3.555 | 0.683 | ||
| Positive | 9 (24.3%) | 10 (28.6%) | |||
| Negative | 28 (75.7%) | 25 (71.4%) | |||
| P53 status | 1.595 | 0.588-4.329 | 0.359 | ||
| Positive | 10 (27%) | 13 (37.1%) | |||
| Negative | 27 (73%) | 22 (92.9%) | |||
OR, Odd ratio; DSCI, ductal carcinoma in situ; PR, progesterone receptor.